ImmunityBio IBRX Q2 2026: ANKTIVA Revenue Surges 94%, EPS Miss Explained
As seen on the 24/7 Wall St. homepage on August 4, 2026.
ANKTIVA revenue grew 94% year over year for an eighth straight quarter of sequential gains, and the EPS miss came from non-cash charges on warrant and derivative fair value tied to the stock's own climb. An FDA decision on a broader bladder cancer label is set for January 6, 2027.
Continue ReadingShow less
ImmunityBio reported Q2 2026 revenue of $51.24 million, beating the $49.70 million consensus estimate by roughly 3%. That figure marks the eighth consecutive quarter of sequential revenue gains for ANKTIVA, the company's flagship bladder cancer therapy, with sales up 94% compared to the same period a year ago. The revenue trajectory has been steep: ANKTIVA generated just $1.05 million in Q2 2024, and has climbed steadily to $51.24 million by Q2 2026.
The headline EPS miss — a reported loss of $0.22 against an estimated loss of $0.08, a gap of 175% — was driven by non-cash charges tied to warrant and derivative fair value adjustments linked to the stock's own price appreciation. Because those charges move with the share price rather than with the underlying business, they can distort the bottom line without reflecting a deterioration in operations. Investors focused on the commercial trajectory of ANKTIVA may look through that accounting noise.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
The next major catalyst on the calendar is an FDA decision on a broader bladder cancer label, currently set for January 6, 2027. An expanded indication could meaningfully widen the addressable patient population for ANKTIVA and accelerate the revenue growth that has already defined the past eight quarters.
Mentioned: IBRX